iqvia holdings inc. - IQV

IQV

Close Chg Chg %
227.14 0.50 0.22%

Closed Market

227.64

+0.50 (0.22%)

Volume: 535.17K

Last Updated:

Dec 30, 2025, 3:59 PM EDT

Company Overview: iqvia holdings inc. - IQV

IQV Key Data

Open

$226.84

Day Range

225.59 - 228.28

52 Week Range

134.65 - 234.30

Market Cap

$38.68B

Shares Outstanding

170.30M

Public Float

168.79M

Beta

1.37

Rev. Per Employee

N/A

P/E Ratio

31.15

EPS

$7.35

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.36M

 

IQV Performance

1 Week
 
0.34%
 
1 Month
 
-1.01%
 
3 Months
 
26.80%
 
1 Year
 
15.87%
 
5 Years
 
27.08%
 

IQV Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 27
Full Ratings ➔

About iqvia holdings inc. - IQV

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

IQV At a Glance

IQVIA Holdings, Inc.
2400 Ellis Road
Durham, North Carolina 27703
Phone 1-919-998-2000 Revenue 15.41B
Industry Biotechnology Net Income 1.37B
Sector Health Technology 2024 Sales Growth 2.954%
Fiscal Year-end 12 / 2025 Employees 88,000
View SEC Filings

IQV Valuation

P/E Current 31.152
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 26.249
Price to Sales Ratio 2.339
Price to Book Ratio 5.704
Price to Cash Flow Ratio 13.27
Enterprise Value to EBITDA 14.388
Enterprise Value to Sales 3.16
Total Debt to Enterprise Value 0.297

IQV Efficiency

Revenue/Employee 175,056.818
Income Per Employee 15,602.273
Receivables Turnover 4.755
Total Asset Turnover 0.575

IQV Liquidity

Current Ratio 0.838
Quick Ratio 0.838
Cash Ratio 0.265

IQV Profitability

Gross Margin 27.66
Operating Margin 14.729
Pretax Margin 10.834
Net Margin 8.913
Return on Assets 5.125
Return on Equity 22.547
Return on Total Capital 6.683
Return on Invested Capital 7.075

IQV Capital Structure

Total Debt to Total Equity 238.652
Total Debt to Total Capital 70.471
Total Debt to Total Assets 53.827
Long-Term Debt to Equity 218.048
Long-Term Debt to Total Capital 64.387
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Iqvia Holdings Inc. - IQV

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
13.88B 14.42B 14.96B 15.40B
Sales Growth
+22.20% +3.90% +3.77% +2.95%
Cost of Goods Sold (COGS) incl D&A
10.50B 10.51B 10.87B 11.14B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.26B 1.13B 1.13B 1.11B
Depreciation
147.00M 160.00M 151.00M 149.00M
Amortization of Intangibles
1.12B 970.00M 974.00M 965.00M
COGS Growth
+19.46% +0.14% +3.41% +2.52%
Gross Income
3.38B 3.91B 4.09B 4.26B
Gross Income Growth
+31.54% +15.55% +4.73% +4.10%
Gross Profit Margin
+24.37% +27.10% +27.35% +27.66%
2021 2022 2023 2024 5-year trend
SG&A Expense
1.96B 2.07B 2.05B 1.99B
Research & Development
- - - -
-
Other SG&A
1.96B 2.07B 2.05B 1.99B
SGA Growth
+9.78% +5.45% -0.87% -2.97%
Other Operating Expense
- - - -
-
Unusual Expense
3.00M 13.00M 32.00M (4.00M)
EBIT after Unusual Expense
1.42B 1.82B 2.01B 2.27B
Non Operating Income/Expense
67.00M (67.00M) 170.00M 107.00M
Non-Operating Interest Income
6.00M 13.00M 36.00M 47.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
354.00M 394.00M 719.00M 711.00M
Interest Expense Growth
-12.16% +11.30% +82.49% -1.11%
Gross Interest Expense
354.00M 394.00M 719.00M 711.00M
Interest Capitalized
- - - -
-
Pretax Income
1.13B 1.36B 1.46B 1.67B
Pretax Income Growth
+202.41% +20.83% +7.04% +14.39%
Pretax Margin
+8.13% +9.45% +9.75% +10.83%
Income Tax
163.00M 260.00M 101.00M 301.00M
Income Tax - Current - Domestic
16.00M 24.00M 21.00M 44.00M
Income Tax - Current - Foreign
293.00M 358.00M 349.00M 386.00M
Income Tax - Deferred - Domestic
(106.00M) (94.00M) (236.00M) (116.00M)
Income Tax - Deferred - Foreign
(40.00M) (28.00M) (33.00M) (13.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
971.00M 1.09B 1.36B 1.37B
Minority Interest Expense
- - - 5.00M
-
Net Income
966.00M 1.09B 1.36B 1.37B
Net Income Growth
+246.24% +12.94% +24.47% +1.10%
Net Margin Growth
+6.96% +7.57% +9.08% +8.91%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
966.00M 1.09B 1.36B 1.37B
Preferred Dividends
- - - -
-
Net Income Available to Common
966.00M 1.09B 1.36B 1.37B
EPS (Basic)
5.047 5.8156 7.3885 7.5731
EPS (Basic) Growth
+246.06% +15.23% +27.05% +2.50%
Basic Shares Outstanding
191.40M 187.60M 183.80M 181.30M
EPS (Diluted)
4.9538 5.724 7.2893 7.4864
EPS (Diluted) Growth
+246.23% +15.55% +27.35% +2.70%
Diluted Shares Outstanding
195.00M 190.60M 186.30M 183.40M
EBITDA
2.68B 2.97B 3.17B 3.38B
EBITDA Growth
+29.63% +10.63% +6.67% +6.89%
EBITDA Margin
+19.32% +20.58% +21.15% +21.96%

Snapshot

Average Recommendation BUY Average Target Price 251.80
Number of Ratings 27 Current Quarters Estimate 2.946
FY Report Date 03 / 2026 Current Year's Estimate 12.93
Last Quarter’s Earnings 3.40 Median PE on CY Estimate N/A
Year Ago Earnings 11.893 Next Fiscal Year Estimate 14.336
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 16 16 24 20
Mean Estimate 2.95 3.03 12.93 14.34
High Estimates 3.12 3.19 13.45 15.05
Low Estimate 2.82 2.90 12.35 13.45
Coefficient of Variance 2.61 2.69 1.69 2.52

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 19 19 18
OVERWEIGHT 4 4 2
HOLD 4 4 6
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Overweight

Insider Actions for Iqvia Holdings Inc. - IQV

Date Name Shares Transaction Value
Jul 29, 2025 John G. Danhakl Director 2,614 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 Colleen A. Goggins Director 4,521 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 James A. Fasano Director 3,870 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 Leslie Wims Morris Director 4,589 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 13, 2025 W. Richard Staub See Remarks 16,896 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $206.97 per share 3,496,965.12
Feb 13, 2025 Ari Bousbib See Remarks; Director 837,083 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $65.16 per share 54,544,328.28
Feb 13, 2025 Ari Bousbib See Remarks; Director 810,498 Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 Non-derivative transaction at $206.97 per share 167,748,771.06
Feb 13, 2025 Ari Bousbib See Remarks; Director 807,163 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $206.97 per share 167,058,526.11
Feb 13, 2025 Ari Bousbib See Remarks; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 13, 2025 Eric M. Sherbet See Remarks 21,108 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $206.97 per share 4,368,722.76
Feb 13, 2025 Ronald Earl Bruehlman See Remarks 34,569 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $206.97 per share 7,154,745.93
Feb 13, 2025 Bhavik Patel See Remarks 1,124 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $206.97 per share 232,634.28
Feb 13, 2025 Keriann Cherofsky See Remarks 3,459 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $206.97 per share 715,909.23

Iqvia Holdings Inc. in the News